Adj A/Prof Chee Cheng Ean

Find a Doctor

2024/03/11

Adj A/Prof Chee Cheng Ean

Designations:

Senior Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore
Adjunct Associate Professor, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore
Executive Director, National University Cancer Institute, Singapore

Qualifications:

BSc (Hons), MBBS (Lond), ABIM (Int Med), ABIM (Med Onc), ABIM (Hem)

Specialties/Sub-specialties:

Medical Oncology

Special Interests:

Gastrointestinal Cancers, Phase I Clinical Trials

Make an Appointment

Contact Us:

Find Out More:

www.ncis.com.sg/

Make an Appointment

Biosketch

Adj A/Prof Chee Cheng Ean is the Executive Director of the National University Cancer Institute, Singapore. In this role, she provides leadership and direction, facilitates operations and is responsible for implementing strategic initiatives for NCIS (pronounced N-CIS), which is the only public, academic cancer center in Singapore treating both pediatric and adult cancers in one facility.

Adj A/Prof Chee is also a senior consultant, gastrointestinal (GI) oncologist and clinician investigator. Her portfolio includes clinical and research initiatives in precision oncology and clinical trials involving novel therapeutics in GI cancers which have been awarded institutional and national grant funding. She also leads the cancer survivorship programme at NCIS and is a proponent of value-based healthcare initiatives.

Journals & Publications

Chee CE, Meropol NJ. Current Status of Gene Expression Profiling to Assist Decision Making in Stage II Colon Cancer. Oncologist. 2014; 19(7): 704-11.
Chee CE, Ashrani AA, Marks RS, Petterson TM, Bailey KR, Melton LJ 3rd, Heit JA. Predictors of Venous Thromboembolism Recurrence and Bleeding Among Active Cancer Patients: A Population-Based Cohort Study. Blood. 2014; 123(25): 3972-8.
Chee CE, Krishnamurthi S, Nock CJ, Meropol NJ, Gibbons J, Fu P, Bokar J, Teston L, O'Brien T, Gudena V, Reese A, Bergman M, Saltzman J, Wright JJ, Dowlati A, Brell JM. Phase II Study of Dasatinib (BMS-354825) in Patients with Metastatic Adenocarcinoma of the Pancreas. Oncologist. 2013; 18(10): 1091-2.
Yang ZJ, Chee CE, Huang S, Sinicrope FA. The Role of Autophagy in Cancer: Therapeutic Implications. Mol Cancer Ther. 2011; 10(9): 1533-41.
Yang ZJ, Chee CE, Huang S, Sinicrope FA. Autophagy Modulation for Cancer Therapy. Cancer Biol Ther. 2011; 11(2): 169-76.
Larsen JT, Chee CE, Lust JA, Greipp PR, Rajkumar SV. Reduction in Plasma Cell Proliferation Following Initial Therapy in Newly Diagnosed Multiple Myeloma Measures Treatment Response and Predicts Improved Survival. Blood. 2011; 118(10): 2702-7.
Chee CE, Sinicrope FA. Targeted Therapeutic Agents for Colorectal Cancer. Gastroenterol Clin North Am. 2010; 39(3): 601-13.
Chee CE, Jett JR, Bernath AM, Foster NR, Nelson GD, Molina J, Nikcevich DA, Steen PD, Flynn PJ, Rowland KM. Phase II Trial of Pemetrexed Disodium and Carboplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer, N0423. Cancer. 2010; 116(10): 2382-9.
Chee CE, Kumar S, Larson DR, Kyle RA, Dispenzieri A, Gertz MA, Colby CL, Rajkumar SV. The Importance of Bone Marrow Examination in Determining Complete Response to Therapy in Patients with Multiple Myeloma. Blood. 2009; 114(13): 2617-8.
Chee CE, Steensma DP, Wu W, Hanson CA, Tefferi A. Neither Serum Ferritin nor the Number of Red Blood Cell Transfusions Affect Overall Survival in Refractory Anemia with Ringed Sideroblasts. Am J Hematol. 2008; 83(8): 611-3.

Professional Memberships

American Society of Clinical Oncology
American College of Physicians

2024/05/02

Doctor Details